PIK-III Inhibitor Protocol: Preparation & Assay Guide

PIK-III is a selective, cell-permeable inhibitor of VPS34 (Class III PI3K) widely used in autophagy and endosomal trafficking research to dissect phosphatidylinositol 3-phosphate (PI3P) signaling pathways.

Target

VPS34 (Class III Phosphatidylinositol 3-Kinase)

Primary Application

Inhibition of autophagy and PI3P production in cell-based and biochemical assays

Recommended Solvent

DMSO (for stock solution preparation)

SKU

P413812

Selleck Reference Number

S7683

Storage Condition

Store at -20 °C, protected from light and moisture; aliquot to avoid repeated freeze-thaw cycles

Overview of PIK-III and Its Mechanism of Action

PIK-III (SKU: P413812; Selleck S7683) is a potent and selective small-molecule inhibitor targeting VPS34, the sole Class III phosphatidylinositol 3-kinase (PI3K) in mammalian cells. VPS34 catalyzes the phosphorylation of phosphatidylinositol to generate phosphatidylinositol 3-phosphate (PI3P), a critical lipid second messenger that orchestrates autophagosome nucleation, endosomal sorting, and lysosomal biogenesis.

By selectively blocking VPS34 kinase activity, PIK-III suppresses PI3P production at early endosomes and phagophore assembly sites, effectively halting early-stage autophagy and disrupting endosomal trafficking. Its high selectivity for VPS34 over Class I and Class II PI3K isoforms makes it a preferred pharmacological tool for dissecting VPS34-specific signaling without confounding off-target effects associated with pan-PI3K inhibitors such as wortmannin or LY294002.

Stock Solution Preparation

Recommended solvent: Dissolve PIK-III in sterile, anhydrous dimethyl sulfoxide (DMSO) to prepare a concentrated stock solution. DMSO is the preferred solvent due to PIK-III's limited aqueous solubility.

1. Calculate the required mass: determine the volume of stock solution needed and the desired concentration (typically 10–50 mM for a DMSO stock).
2. Weigh the compound: using an analytical balance, accurately weigh the appropriate amount of PIK-III powder in a clean, dry microcentrifuge tube.
3. Add DMSO: pipette the calculated volume of anhydrous DMSO directly into the tube containing PIK-III powder.
4. Dissolve completely: vortex vigorously for 30–60 seconds, then sonicate in a water bath sonicator for 5–10 minutes if necessary, until a clear solution is obtained. Do not proceed if particulates remain.
5. Aliquot: divide the stock solution into single-use aliquots to minimize freeze-thaw cycles, and store at -20 °C protected from light.

Note: The final DMSO concentration in cell culture medium or assay buffer should not exceed 0.1% (v/v) to avoid solvent cytotoxicity. Prepare working solutions by diluting stock into pre-warmed assay medium immediately before use.

Cell-Based Autophagy Inhibition Assay Protocol

The following general protocol describes how to assess VPS34 inhibition by PIK-III using mammalian cell lines. Optimization of concentration and treatment duration may be required for specific cell types.

Materials Required

• PIK-III stock solution (P413812) in DMSO
• Mammalian cell line of interest (e.g., HeLa, MCF-7, or other)
• Complete cell culture medium appropriate for the cell line
• Autophagy induction agent (e.g., rapamycin or Earle's Balanced Salt Solution for starvation)
• Antibodies or reagents for autophagy markers (e.g., anti-LC3B, anti-WIPI2, or PI3P detection probes)

Procedure

1. Cell seeding: Seed cells at an appropriate density in multi-well plates or dishes 16–24 hours before treatment to achieve 60–80% confluence at the time of treatment.
2. Compound treatment: Dilute PIK-III stock solution into pre-warmed complete medium to the desired working concentration. Typical working concentrations range from 100 nM to 10 µM depending on the assay endpoint; consult literature for cell-type-specific IC50 values. Remove existing medium from cells and replace with PIK-III-containing medium.
3. Incubation: Incubate cells at 37 °C, 5% CO2 for the desired treatment period (commonly 1–4 hours for acute VPS34 inhibition).
4. Autophagy induction (optional co-treatment): For rescue or combination experiments, co-treat with an autophagy inducer as required by the experimental design.
5. Endpoint analysis: Assess autophagy inhibition by immunofluorescence microscopy (LC3B puncta, WIPI2 foci), Western blotting (LC3-I/II conversion, p62/SQSTM1 accumulation), or PI3P detection using FYVE-domain probes.
6. Controls: Include vehicle control (equivalent DMSO concentration) and a positive control for autophagy inhibition (e.g., bafilomycin A1) in every experiment.

Troubleshooting and Tips

The following guidance addresses common issues encountered when working with PIK-III:

• Poor solubility or precipitation in aqueous media: Always prepare stock solutions in anhydrous DMSO and dilute stepwise into aqueous buffer or medium. Warming the medium to 37 °C before dilution can help maintain solubility. Do not exceed the recommended final DMSO concentration of 0.1% (v/v).
• Inconsistent autophagy inhibition: Ensure the stock solution is fully dissolved and that working concentrations are prepared fresh. Variability may also reflect differences in basal autophagy flux between cell lines. Titrate PIK-III concentrations and time points empirically for each cell model.
• Cytotoxicity at high concentrations: Assess cell viability (e.g., MTT or CellTiter-Glo assay) at each concentration tested. Use the lowest efficacious concentration to minimize off-target cytotoxic effects.
• Compound degradation: Avoid repeated freeze-thaw cycles by using single-use aliquots. Do not store working solutions; prepare them freshly before each experiment. Protect all solutions from light.
• Selectivity concerns: At concentrations exceeding recommended ranges, PIK-III may inhibit additional PI3K family members. Keep working concentrations within validated ranges reported in peer-reviewed literature.

Safety, Handling and Regulatory Notes

PIK-III is intended for research use only and is not approved for human or veterinary diagnostic or therapeutic applications. The following precautions should be observed:

• Personal protective equipment (PPE): Wear appropriate laboratory coat, chemical-resistant gloves, and eye protection when handling PIK-III and its solutions.
• Hazard information: Specific GHS hazard classifications for PIK-III should be consulted in the Safety Data Sheet (SDS) provided by Aladdin Scientific. Handle as a potentially hazardous research chemical.
• Waste disposal: Dispose of PIK-III solutions and contaminated materials in accordance with local institutional, regional, and national regulations governing chemical waste disposal.
• DMSO penetration: Note that DMSO can rapidly penetrate skin and may carry dissolved compounds transdermally. Exercise particular caution when handling PIK-III solutions in DMSO; use solvent-resistant gloves.
• Documentation: Maintain accurate records of lot numbers, concentrations prepared, and experimental conditions for reproducibility and compliance purposes.

Frequently asked questions

What is the recommended starting concentration of PIK-III for cell-based autophagy assays?

A concentration range of 100 nM to 10 µM is commonly used as a starting point, depending on the cell line and assay endpoint. It is advisable to perform a dose-response experiment to determine the optimal concentration for your specific cell model, as sensitivity to VPS34 inhibition can vary between cell types.

Can PIK-III be dissolved in aqueous buffers directly?

PIK-III has limited aqueous solubility and should be dissolved initially in anhydrous DMSO to prepare a concentrated stock solution. Working solutions are then prepared by diluting the DMSO stock into the appropriate aqueous medium or buffer. The final DMSO concentration in the working solution should not exceed 0.1% (v/v) to avoid solvent-related cytotoxicity.

How should PIK-III be stored to maintain stability?

PIK-III should be stored at -20 °C in a dry, dark environment. Stock solutions in DMSO should be aliquoted into single-use volumes to avoid repeated freeze-thaw cycles, which can degrade the compound over time. Working solutions should be prepared fresh before each experiment and not stored.

What controls should be included when using PIK-III in autophagy experiments?

Every experiment should include a vehicle control containing the same final concentration of DMSO as the PIK-III-treated samples. A positive control for autophagy inhibition, such as bafilomycin A1 (which blocks lysosomal acidification), is also recommended to validate the assay system. An autophagy-induced positive control (e.g., rapamycin-treated or nutrient-starved cells) helps confirm the dynamic range of the assay.

Is PIK-III selective for VPS34 over other PI3K isoforms?

Yes, PIK-III is reported to be a selective inhibitor of VPS34 (Class III PI3K) with significantly lower activity against Class I PI3K isoforms (PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ) and Class II PI3K members. This selectivity makes PIK-III a valuable tool for studying VPS34-specific biology. However, selectivity should be verified at the concentrations used in each experimental system, as very high concentrations may reduce isoform selectivity.

References

1. Dowdle WE, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nature Cell Biology, 2014.
2. Bago R, et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochemical Journal, 2014.
3. Selleck Chemicals. PIK-III Product Information Sheet, Catalog No. S7683.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.